Systematic review with meta-analysis: the efficacy and safety of #tenofovir to prevent mother-to-child transmission of hepatitis #B virus
http://onlinelibrary.wiley.com/doi/10.1111/apt.14068/abstract
For pregnant women with high hepatitis B virus DNA levels, tenofovir administration in the second or third trimester can prevent mother to child transmission when combined with hepatitis B immunoglobulin and the hepatitis B vaccine. Tenofovir is safe and tolerable for both the mother and foetus.
http://onlinelibrary.wiley.com/doi/10.1111/apt.14068/abstract
For pregnant women with high hepatitis B virus DNA levels, tenofovir administration in the second or third trimester can prevent mother to child transmission when combined with hepatitis B immunoglobulin and the hepatitis B vaccine. Tenofovir is safe and tolerable for both the mother and foetus.
Wiley
Systematic review with meta‐analysis: the efficacy and safety of tenofovir to prevent mother‐to‐child transmission of hepatitis…
Preventing mother to child transmission of chronic hepatitis B infection in the setting of a high maternal viral load is challenging. The idea has emerged from antepartum tenofovir treatment with combination...
!!
#Tenofovir gel for prevention of #herpes simplex virus type-2 acquisition: findings from the VOICE Trial
https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiz045/5315462?redirectedFrom=fulltext
Genital infection with herpes simplex virus type-2 (HSV-2) is common, and increases risk of HIV transmission and acquisition. Pericoital use of tenofovir (TFV) gel provided protection from HSV-2 acquisition in the CAPRISA 004 Study.
Of 566 participants at risk for HSV-2, 532 (94%) had first quarter plasma TFV and end-of-study HSV-2 serology available. Over follow-up of 501 PY, 92 incident HSV-2 cases occurred: 77 in women with no plasma TFV detected and 15 with plasma TFV (incidence 20.6 (16.2-25.7) vs. 11.9 (6.6-19.6), respectively). Plasma TFV detection was associated with trend towards reduced risk of HSV-2 seroconversion (unadjusted HR 0.59 (0.34-1.02; P=0.060); HR adjusted for site, age, ≥ 2 sex partners, hormonal contraception, anal sex, and HIV status 0.60 (0.33-1.08; P=0.086)).
Conclusions
Detection of plasma TFV among TFV gel users was associated with trend towards reduced risk of HSV-2 acquisition after controlling for sexual behavior and HIV-1 acquisition.
#Tenofovir gel for prevention of #herpes simplex virus type-2 acquisition: findings from the VOICE Trial
https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiz045/5315462?redirectedFrom=fulltext
Genital infection with herpes simplex virus type-2 (HSV-2) is common, and increases risk of HIV transmission and acquisition. Pericoital use of tenofovir (TFV) gel provided protection from HSV-2 acquisition in the CAPRISA 004 Study.
Of 566 participants at risk for HSV-2, 532 (94%) had first quarter plasma TFV and end-of-study HSV-2 serology available. Over follow-up of 501 PY, 92 incident HSV-2 cases occurred: 77 in women with no plasma TFV detected and 15 with plasma TFV (incidence 20.6 (16.2-25.7) vs. 11.9 (6.6-19.6), respectively). Plasma TFV detection was associated with trend towards reduced risk of HSV-2 seroconversion (unadjusted HR 0.59 (0.34-1.02; P=0.060); HR adjusted for site, age, ≥ 2 sex partners, hormonal contraception, anal sex, and HIV status 0.60 (0.33-1.08; P=0.086)).
Conclusions
Detection of plasma TFV among TFV gel users was associated with trend towards reduced risk of HSV-2 acquisition after controlling for sexual behavior and HIV-1 acquisition.
OUP Academic
Tenofovir gel for prevention of herpes simplex virus type-2 acquisition: findings from the VOICE Trial
AbstractBackground. Genital infection with herpes simplex virus type-2 (HSV-2) is common, and increases risk of HIV transmission and acquisition. Pericoital us